Lancet Rheumatology

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	731
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	719
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	251
A disseminated gonococcal infection with spinal locations	186
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	161
Reigniting the burnt-out health-care workforce	146
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	133
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	133
Research in Brief	131
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	112
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	110
Biological disease-modification in axial spondyloarthritis: insights from MRI	109
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	91
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	91
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	89
Women in rheumatology in Africa	87
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	84
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	81
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	80
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	76
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	71
Can contextual factors improve clarity of the results from clinical trials of low back pain?	71
Early-stage Dupuytren's disease treatment; a promising next step?	70
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	63
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	60

Pausing drugs and spacing vaccines: an open question – Authors' reply	57
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	57
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	54
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	53
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	53
Composite endpoints for Sjögren's Syndrome	52
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	52
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	50
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	49
Research in Brief	48
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	44
Assessing glucocorticoid toxicity: are the measures sensitive enough?	44
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	43
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	42
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	42
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	42
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	41
Let's talk about sex in interstitial lung disease	40
Clinical trial design: time to accelerate the pace of change?	40
Biosimilars and the era of interchangeability	40
Kanon Jatuworapruk: bringing out the enjoyment in life	39
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	38
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	38
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	38
Mental health before and during the pandemic in people with systemic sclerosis	38
Urgent reform needed for homecare medicines services	38
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	37
Research in Brief	36
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	36
Global access to biological disease-modifying drugs	36
Additional SARS-CoV-2 vaccine doses: a little is better than none	35
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	35
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	34
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19	33
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a p	32
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	32
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	32
Tackling heterogeneity in Sjögren's disease	32
Research in Brief	31
COVID-19: is the rush to boost backed by science?	30
Who will respond to type I interferon receptor blockade in SLE?	29
Central sensitisation: causes, therapies, and terminology	29
Research in Brief	28
Suspending methotrexate for 2 weeks after COVID-19 vaccination	28
Call for papers: Sex and gender in rheumatology	28
The 2024 US election—voting for equitable health care	27
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	27
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	27

Are we ready for home spirometry for systemic sclerosis-associated ILD?	27
Advancing research and equity through collaboration	27
Explanation for substandard of care comparators in rheumatology randomised trial protocols	26
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal	26
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	25
JIA care under the microscope	24
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	24
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	23
Better diagnostic tools needed for biopsy-negative giant cell arteritis	23
Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)	23
Digital self-management for back pain in the UK	23
Telemedicine: is the new normal fit for purpose?	23
Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	23
Clinician-reported outcome measures in lupus trials: a problem worth solving	22
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	22
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	22
Polychondritis in a child	22
Cranial involvement in giant cell arteritis	22
Penélope Palominos: rheumatology by sight and touch	22
Jean Liew: from Bronte scholar to social media influencer	21
COP27 Climate Change Conference: urgent action needed for Africa and the world	21
Reconciling immunotherapy and autoimmunity: not for the faint of heart	21
The impact of COVID-19 on care of early inflammatory arthritis in the UK	21
Pain and wellbeing in young people with arthritis	21
Calcinosis cutis universalis secondary to scleroderma-polymyositis overlap syndrome	21
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	20
Coronary polyarteritis nodosa	20
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	20
Arthritis and fertility: time to think about men	20
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	20
Beneficial side-effects of colchicine for patients with gout	20
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	20
Deciphering the cytokine fingerprint of macrophage activation syndrome	20
For SLE activity and glucocorticoids: aim low	20
Microscopic polyangiitis presenting with retinal frosted branch angiitis	20
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	20
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses	19
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	19
Research in Brief	19
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	19
Gout in central Asia: a few things make a big difference	19
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation – Authors' reply	19
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	19
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	19
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	19
Research in Brief	18
A role for interleukin-1 receptor antagonism in severe COVID-19?	18
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	18
Thank you to our peer reviewers in 2021	18
DAVIX: a vascular outcome measure in systemic sclerosis	18
David Liew: where communication meets medicine	18
Composite endpoints for Sjögren's Syndrome – Authors' reply	18
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	18
Digital remote monitoring in rheumatology: using health economics to support wider adoption	17
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease	17
Ustekinumab with or without methotrexate for psoriatic arthritis?	17
Correction to Lancet Rheumatol 2023; 5: e461–73	17
Rheumatology congresses post COVID-19: we cannot regress	17
Prevention of psoriatic arthritis: the next frontier	17
Prize trends in rheumatology: the Gender Award Gap	16
Coronary polyarteritis nodosa in a young adult	16
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	16
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	16
Advancing predictive accuracy for shoulder replacement surgery	16
Titilola (Lola) Falasinnu: looking out for the overlooked	15
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	15
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	15
Socioeconomic deprivation worsens rheumatoid arthritis	15
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	15
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	15
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	15
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	15
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	14
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	14
Research in Brief	14
Research in Brief	14
Industry involvement in rheumatology consensus-based recommendations: a systematic review	14
Research in Brief	14
Research in Brief	13
The influence of safety warnings on the prescribing of JAK inhibitors	13

Palliative care in patients with rheumatic diseases	13
Susac syndrome: challenges of interpreting treatment data in a rare disease	13
Correction to Lancet Rheumatol 2022; 4: e177–87	13
Vasculitis: the promising road ahead	13
Correction to Lancet Rheumatol 2022; 4: e853–63	13
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	12
Cardiovascular risk in gout: time for action	12
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	12
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	12
The same genotype gives rise to a spectrum of disorders	12
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	12
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	12
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	12
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study	12
Debate over interventional procedures for chronic spine pain	12
Rheumatic cognitive impairment: a new clinical entity?	12
Central sensitisation: causes, therapies, and terminology – Authors' reply	11
Calcium pyrophosphate deposition disease	11
Getting better at quantifying the toxicity of glucocorticoids	11
Predictors of pregnancy outcomes in SLE	11
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	11
How should we define disease and outcomes in axial psoriatic arthritis?	11
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	11
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	11
Michael Barrett: navigating hostile terrain	11
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	11
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	10
Expanding role of biomarkers in characterising hyperinflammatory syndromes – Authors' reply	10
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	10
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	10
Predictors of pregnancy outcomes in SLE	10
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort	10
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	10
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply	10
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	10
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	10
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	9
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	9
Kimberly Templeton: creative change maker	9
Contesting the BACPAP consortium's consensus – Authors' reply	9
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	9
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	9
Correction to Lancet Rheumatol 2021; 3: e789–97	9
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	9
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	9
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	9
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	9
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	9